Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells

Drug resistance is a major obstacle in the targeted therapy of melanoma using BRAF/MEK inhibitors. This study was to identify BRAF V600E-associated oncogenic pathways that predict resistance of BRAF-mutated melanoma to BRAF/MEK inhibitors. We took in silico approaches to analyze the activities of 24 cancer-related pathways in melanoma cells and identify those whose activation was associated with BRAF V600E and used the support vector machine (SVM) algorithm to predict the resistance of BRAF-mutated melanoma cells to BRAF/MEK inhibitors. We then experimentally confirmed the in silico findings. In a microarray gene expression dataset of 63 melanoma cell lines, we found that activation of multiple oncogenic pathways preferentially occurred in BRAF-mutated melanoma cells. This finding was reproduced in 5 additional independent melanoma datasets. Further analysis of 46 melanoma cell lines that harbored BRAF mutation showed that 7 pathways, including TNFα, EGFR, IFNα, hypoxia, IFNγ, STAT3, and MYC, were significantly differently expressed in AZD6244-resistant compared with responsive melanoma cells. A SVM classifier built on this 7-pathway activation pattern correctly predicted the response of 10 BRAF-mutated melanoma cell lines to the MEK inhibitor AZD6244 in our experiments. We experimentally showed that TNFα, EGFR, IFNα, and IFNγ pathway activities were also upregulated in melanoma cell A375 compared with its sub-line DRO, while DRO was much more sensitive to AZD6244 than A375. In conclusion, we have identified specific oncogenic pathways preferentially activated in BRAF-mutated melanoma cells and a pathway pattern that predicts resistance of BRAF-mutated melanoma to BRAF/MEK inhibitors, providing novel clinical implications for melanoma therapy.

[1]  B. Wielockx,et al.  Hypoxia‐inducible factors as key regulators of tumor inflammation , 2013, International journal of cancer.

[2]  R. Sullivan,et al.  MAP kinase signaling and inhibition in melanoma , 2013, Oncogene.

[3]  M. Gore,et al.  Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. , 2013, Cancer discovery.

[4]  Jin Yuan,et al.  Mechanism of TNF-α autocrine effects in hypoxic cardiomyocytes: initiated by hypoxia inducible factor 1α, presented by exosomes. , 2012, Journal of molecular and cellular cardiology.

[5]  P. Hirth,et al.  Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.

[6]  M. Xing,et al.  Epigenetic genes regulated by the BRAFV600E signaling are associated with alterations in the methylation and expression of tumor suppressor genes and patient survival in melanoma. , 2012, Biochemical and biophysical research communications.

[7]  R. Weichselbaum,et al.  Molecular Pathways Molecular Pathways : Interferon / Stat 1 Pathway : Role in the Tumor Resistance to Genotoxic Stress and Aggressive Growth , 2012 .

[8]  B. Wilson,et al.  Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor–mediated upregulation of caveolin-1 , 2012, Proceedings of the National Academy of Sciences.

[9]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[10]  D. Rimm,et al.  β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. , 2011, Cancer cell.

[11]  K. Smalley,et al.  Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. , 2011, Biochemical pharmacology.

[12]  Michael L. Gatza,et al.  Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes , 2011, Breast Cancer Research.

[13]  J. Nevins,et al.  Use of gene expression and pathway signatures to characterize the complexity of human melanoma. , 2011, The American journal of pathology.

[14]  Chih-Jen Lin,et al.  LIBSVM: A library for support vector machines , 2011, TIST.

[15]  T. Luger,et al.  RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells. , 2011, The Journal of investigative dermatology.

[16]  René Bernards,et al.  Taming the dragon: genomic biomarkers to individualize the treatment of cancer , 2011, Nature Medicine.

[17]  J. Grandis,et al.  STAT3 signaling: anticancer strategies and challenges. , 2011, Molecular interventions.

[18]  B. Pützer,et al.  Predicting and preventing melanoma invasiveness: advances in clarifying E2F1 function , 2010, Expert review of anticancer therapy.

[19]  Li-E. Wang,et al.  Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma , 2010, Clinical Cancer Research.

[20]  Y. Samuels,et al.  Analysis of the genome to personalize therapy for melanoma , 2010, Oncogene.

[21]  S. Mocellin,et al.  The dual role of tumor necrosis factor (TNF) in cancer biology. , 2010, Current Medicinal Chemistry.

[22]  Michael L. Gatza,et al.  A pathway-based classification of human breast cancer , 2010, Proceedings of the National Academy of Sciences.

[23]  B. Taylor,et al.  Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). , 2010, Cancer research.

[24]  M. Karin,et al.  Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. , 2010, Cytokine & growth factor reviews.

[25]  Hong Sun,et al.  Mechanisms of c-Myc Degradation by Nickel Compounds and Hypoxia , 2009, PloS one.

[26]  T. Giordano,et al.  C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells , 2008, Oncogene.

[27]  Christopher Korch,et al.  Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. , 2008, The Journal of clinical endocrinology and metabolism.

[28]  W. Tong,et al.  Transactivation of EGF receptor and ErbB2 protects intestinal epithelial cells from TNF-induced apoptosis , 2008, Proceedings of the National Academy of Sciences.

[29]  K. Hoek.  DNA microarray analyses of melanoma gene expression: a decade in the mines. , 2007, Pigment cell research.

[30]  N. Hayward,et al.  Confirmation of a BRAF mutation-associated gene expression signature in melanoma. , 2007, Pigment cell research.

[31]  C. Prives,et al.  Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? , 2007, Oncogene.

[32]  M. West,et al.  Embracing the complexity of genomic data for personalized medicine. , 2006, Genome research.

[33]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[34]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[35]  W. Jelkmann,et al.  Review: hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions. , 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[36]  E. Zandi,et al.  Tumor Necrosis Factor α-dependent Drug Resistance to Purine and Pyrimidine Analogues in Human Colon Tumor Cells Mediated through IKK* , 2005, Journal of Biological Chemistry.

[37]  M. Marra,et al.  Apoptosis induced by interferon‐α and antagonized by EGF is regulated by caspase‐3‐mediated cleavage of gelsolin in human epidermoid cancer cells , 2004, Journal of cellular physiology.

[38]  S. Enosawa,et al.  Hypoxia/re-oxygenation-induced, redox-dependent activation of STAT1 (signal transducer and activator of transcription 1) confers resistance to apoptotic cell death via hsp70 induction. , 2004, The Biochemical journal.

[39]  M. Lens,et al.  Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma , 2004, The British journal of dermatology.

[40]  N. Matsubara,et al.  Combination of tumor necrosis factor alpha and interferon alpha induces apoptotic cell death through a c-myc-dependent pathway in p53 mutant H226br non-small-cell lung cancer cell line. , 2001, Experimental cell research.

[41]  K. Moberg,et al.  Tumor necrosis factor and gamma-interferon repress transcription from the c-myc P2 promoter by reducing E2F binding activity. , 1999, International journal of oncology.

[42]  P. Tagliaferri,et al.  α‐interferon potentiates epidermal growth factor receptor‐mediated effects on human epidermoid carcinoma KB cells , 1995 .

[43]  S. Kosak,et al.  Interferon-alpha-2b downregulation of oncogenes H-ras, c-raf-2, c-kit, c-myc, c-myb and c-fos in ESKOL, a hairy cell leukemic line, results in temporal perturbation of signal transduction cascade. , 1994, Leukemia research.

[44]  Aixia Guo,et al.  Gene Selection for Cancer Classification using Support Vector Machines , 2014 .

[45]  M. Held,et al.  Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. , 2013, Cancer discovery.

[46]  T. Eberlein,et al.  Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .

[47]  Roberto Piva,et al.  The anaplastic lymphoma kinase in the pathogenesis of cancer , 2008, Nature Reviews Cancer.

[48]  S. Gerber,et al.  IFN-alpha induces transcription of hypoxia-inducible factor-1alpha to inhibit proliferation of human endothelial cells. , 2008, Journal of immunology.

[49]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[50]  P. Rothberg,et al.  Oncogenes and cancer. , 1983, Cancer investigation.